Boundless Bio (BOLD) 10% Owner Kevin Tang Buys 63,969 Shares

What Happened

• Kevin Tang, reported as a 10% owner of Boundless Bio (BOLD), purchased a total of 63,969 shares in open-market transactions between July 14 and July 16, 2026, for aggregate reported proceeds of $155,646.
  • 2026-07-14: 43,878 shares at a reported weighted-average price of $2.43 = $106,624.
  • 2026-07-15: 1,600 shares at $2.44 = $3,904.
  • 2026-07-16: 18,491 shares at $2.44 = $45,118.
• These are purchases (a net buy signal) rather than sales.

Key Details

• Transaction dates & prices: July 14–16, 2026; reported weighted-average prices between $2.41 and $2.44 (footnotes indicate some lots were at $2.44 and others in the $2.43–$2.44 range).
• Total acquired: 63,969 shares for about $155,646.
• Shares owned after transaction: The filing notes related entities beneficially owned by the Reporting Persons — Tang Capital Partners, LP (654,055), Tang Capital Partners International, LP (891,914), Tang Capital Partners III, Inc. (654,048), and Tang Capital Partners IV, Inc. (654,055). Mr. Tang has a pecuniary interest in the shares held by these entities (see Footnote F2).
• Notable footnotes: F1 notes reported prices are weighted averages and purchases occurred across multiple transactions; F3/F4 specify some lots were at $2.44 and some in the $2.43–$2.44 range.
• Filing timeliness: Report filed July 16, 2026 covering trades on July 14–16 — filed within typical Form 4 timing (not marked late).

Context

• As a 10% owner with interests via multiple Tang Capital entities, these purchases reflect additional insider buying but are not the same as routine executive compensation-related trades. Purchases by insiders can be informative to investors, but they do not by themselves explain motivation or future company performance.